checkAd

     161  0 Kommentare BioVie Inc. Announces Proposed Public Offering of Common Stock - Seite 2

    Forward-Looking Statements
    This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

    For Investor Relations Inquiries:
    Bruce Mackle
    Managing Director, LifeSci Advisors, LLC
    bmackle@lifesciadvisors.com

    Lesen Sie auch

    For Media Relations Inquiries:
    Melyssa Weible
    Managing Partner, Elixir Health Public Relations
    mweible@elixirhealthpr.com

    Seite 2 von 2



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    BioVie Inc. Announces Proposed Public Offering of Common Stock - Seite 2 CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) - BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and …